Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20640447 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003713 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003696 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL20640411 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003705 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003661 | 0.80 | CYP2D6 (0.51) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003668 | 0.80 | CYP2D6 (0.51) | CYP2D6CYP2C9CYP2C19LAP3GRIN2D | |
| SCHEMBL9003822 | 0.77 | CYP2D6 (0.44) | CYP2D6CYP2C9CYP2C19LAP3ALDH1A1 | |
| SCHEMBL9003813 | 0.77 | CYP2D6 (0.44) | CYP2D6CYP2C9CYP2C19LAP3ALDH1A1 | |
| SCHEMBL1829246 | 0.75 | CYP2D6 (0.45) | CYP2D6CYP2C9CYP2C19LAP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-5538958-A | NMDA antagonists | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5500419-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0418863-B1 | NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5326756-A | R-4-oxo-5 phosphononorvaline used as NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5095009-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-10 | — | — | US | disclosed |
| EP-0418863-A2 | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | CYP2D6 498/4885CYP2C9 481/4885CYP2C19 239/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | CYP2D6 498/4885CYP2C9 481/4885CYP2C19 239/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | CYP2D6 498/4885CYP2C9 481/4885CYP2C19 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.